MX2019007779A - Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). - Google Patents
Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).Info
- Publication number
- MX2019007779A MX2019007779A MX2019007779A MX2019007779A MX2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- efp
- collagenase
- reducing
- reducing efp
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000029816 Collagenase Human genes 0.000 abstract 3
- 108060005980 Collagenase Proteins 0.000 abstract 3
- 229960002424 collagenase Drugs 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se dirige a un método de tratamiento o reducción de la PEFE en un paciente que comprende la administración de una o múltiples inyecciones de dosis baja de colagenasa a un área afectada por la PEFE. La invención abarca métodos en donde la dosis de colagenasa por inyección está entre alrededor de 50 a alrededor de 200 unidades ABC y/o en donde la concentración de colagenasa está entre alrededor de 50 a alrededor de 2000 unidades ABC/mililitro (ml).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161549863P | 2011-10-21 | 2011-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019007779A true MX2019007779A (es) | 2019-09-04 |
Family
ID=48141393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014004792A MX2014004792A (es) | 2011-10-21 | 2012-10-19 | Metodo de tratamiento o reduccion de efp. |
MX2019007779A MX2019007779A (es) | 2011-10-21 | 2014-04-21 | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014004792A MX2014004792A (es) | 2011-10-21 | 2012-10-19 | Metodo de tratamiento o reduccion de efp. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20140335072A1 (es) |
EP (2) | EP2768523B1 (es) |
JP (5) | JP2014530873A (es) |
AU (5) | AU2012325941A1 (es) |
BR (1) | BR112014009785B1 (es) |
CA (1) | CA2852942C (es) |
DK (2) | DK2768523T3 (es) |
ES (2) | ES2741476T3 (es) |
FI (1) | FI3581199T3 (es) |
HK (1) | HK1201439A1 (es) |
HU (2) | HUE044650T2 (es) |
MX (2) | MX2014004792A (es) |
PL (1) | PL3581199T3 (es) |
PT (2) | PT3581199T (es) |
WO (1) | WO2013059619A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014017229B1 (pt) | 2012-01-12 | 2022-05-17 | Auxilium International Holdings, Inc | Ácido nucleico recombinante, cassette de expressão, vetor, célula hospedeira recombinante, método de produção da colagenase i ou ii, colagenase i ou ii, composição farmacêutica, e método de produção de um produto de droga |
CA2872227A1 (en) | 2012-05-01 | 2013-11-07 | Proteolease Ltd. | Methods for extracting a tooth |
AU2014228477B2 (en) | 2013-03-15 | 2019-05-23 | Biospecifics Technologies Corporation | Treatment method and product for uterine fibroids using purified collagenase |
CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
JP7558654B2 (ja) | 2017-03-01 | 2024-10-01 | エンド ベンチャーズ アンリミテッド カンパニー | セルライトを評価及び処置するための装置及び方法 |
BR112019020394A2 (pt) | 2017-03-28 | 2020-04-22 | Endo Ventures Ltd | método melhorado de produção de colagenase |
WO2020021332A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
WO2020021330A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
WO2020023406A1 (en) * | 2018-07-23 | 2020-01-30 | Nc8, Inc. | Cellulite treatment system and methods |
WO2020058755A1 (en) * | 2018-09-18 | 2020-03-26 | Endo Global Aesthetics Limited | Compositions and methods for treating cellulite |
CA3125007A1 (en) * | 2019-01-06 | 2020-07-09 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
CA3157517A1 (en) | 2019-10-15 | 2021-04-22 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
US20210244642A1 (en) * | 2020-02-10 | 2021-08-12 | Simeon Wall, Jr. | Cellulite eradication methods |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US4524065A (en) * | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
US6958150B2 (en) * | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
HUE038247T2 (hu) * | 2004-05-19 | 2018-10-29 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Nátrium-deoxikolátot tartalmazó injektálható készítmény |
US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
WO2007100590A2 (en) * | 2006-02-22 | 2007-09-07 | Auxilium Pharmaceuticals, Inc. | Methods for treating cellulite |
WO2008101406A1 (en) * | 2007-02-14 | 2008-08-28 | Yolare Dermaceuticals, Llc | Modified mutant collagenase and it's use in fat melting and in scar reduction |
-
2012
- 2012-10-19 JP JP2014537297A patent/JP2014530873A/ja active Pending
- 2012-10-19 WO PCT/US2012/061063 patent/WO2013059619A1/en active Application Filing
- 2012-10-19 PL PL19172643.9T patent/PL3581199T3/pl unknown
- 2012-10-19 EP EP12842537.8A patent/EP2768523B1/en active Active
- 2012-10-19 MX MX2014004792A patent/MX2014004792A/es active IP Right Grant
- 2012-10-19 EP EP19172643.9A patent/EP3581199B1/en active Active
- 2012-10-19 DK DK12842537.8T patent/DK2768523T3/da active
- 2012-10-19 AU AU2012325941A patent/AU2012325941A1/en not_active Abandoned
- 2012-10-19 DK DK19172643.9T patent/DK3581199T3/da active
- 2012-10-19 CA CA2852942A patent/CA2852942C/en active Active
- 2012-10-19 ES ES12842537T patent/ES2741476T3/es active Active
- 2012-10-19 HU HUE12842537 patent/HUE044650T2/hu unknown
- 2012-10-19 BR BR112014009785-2A patent/BR112014009785B1/pt active IP Right Grant
- 2012-10-19 HU HUE19172643A patent/HUE063599T2/hu unknown
- 2012-10-19 FI FIEP19172643.9T patent/FI3581199T3/fi active
- 2012-10-19 PT PT191726439T patent/PT3581199T/pt unknown
- 2012-10-19 ES ES19172643T patent/ES2953560T3/es active Active
- 2012-10-19 PT PT12842537T patent/PT2768523T/pt unknown
-
2014
- 2014-04-17 US US14/255,407 patent/US20140335072A1/en not_active Abandoned
- 2014-04-21 MX MX2019007779A patent/MX2019007779A/es unknown
-
2015
- 2015-02-23 HK HK15101853.7A patent/HK1201439A1/xx unknown
-
2016
- 2016-03-31 AU AU2016202026A patent/AU2016202026A1/en not_active Abandoned
-
2017
- 2017-09-22 JP JP2017183076A patent/JP2018027968A/ja active Pending
- 2017-10-17 AU AU2017248451A patent/AU2017248451B2/en active Active
-
2020
- 2020-02-03 AU AU2020200763A patent/AU2020200763B2/en active Active
- 2020-06-16 JP JP2020103455A patent/JP2020158521A/ja active Pending
-
2022
- 2022-05-04 AU AU2022202987A patent/AU2022202987B2/en active Active
- 2022-06-20 JP JP2022098817A patent/JP2022123073A/ja active Pending
-
2024
- 2024-01-17 US US18/415,270 patent/US20240216485A1/en active Pending
- 2024-06-19 JP JP2024098658A patent/JP2024123126A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
EA201991014A1 (ru) | Лечение диабета | |
MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
WO2012093258A3 (en) | Irf5- related treatment and screening | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
EA201491500A1 (ru) | Способы лечения фиброза | |
SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
NZ630346A (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
IN2014DN09990A (es) | ||
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
MX2014013967A (es) | Un metodo para mejorar el desempeño en pollos para consumo. | |
UA80369U (ru) | Способ лечения мультирезистентного туберкулеза легких | |
MX364643B (es) | USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. | |
UA71921U (ru) | Способ лечения токсической нейроретинопатии алкогольной этиологии | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина | |
RU2013119140A (ru) | Способ лечения вегетососудистой дистонии у детей и подростков | |
EA201201208A1 (ru) | Твердая лекарственная форма, обладающая анорексигенным действием (варианты) | |
UA52171U (ru) | Способ лечения дезадаптации сердечно-сосудистой системы у новорожденных с синдромом аспирации мекония | |
RU2010141350A (ru) | Способ иммунокоррекции у инфицированного вирусом лейкоза крупного рогатого скота | |
MY169877A (en) | Treatment of malphigia coccigera on liver cirrhosis | |
UA46514U (ru) | Способ местного лечения ограниченной склеродермии |